
Jean-Pierre Latere, EsoBiotec CEO
AstraZeneca to buy cell therapy startup for $425M upfront
AstraZeneca said Monday that it has agreed to acquire a cell therapy biotech founded just four years ago for an upfront payment of $425 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.